A multi-targeting pre-clinical candidate against drug-resistant tuberculosis

Parvinder Kaur; Vijay Potluri; Vijay Kamal Ahuja; C N Naveenkumar; Ramya Vadageri Krishnamurthy; Shruthi Thimmalapura Gangadharaiah; Prasad Shivarudraiah; Sumesh Eswaran; Christy Rosaline Nirmal; Balasubramanian Mahizhaveni; Azger Dusthackeer; Rajesh Mondal; Sarah M Batt; Emily J Richardson; Nicholas J Loman; Gurdyal Singh Besra; Radha Krishan Shandil; Shridhar Narayanan

doi:10.1016/j.tube.2021.102104

A multi-targeting pre-clinical candidate against drug-resistant tuberculosis

Parvinder Kaur, Vijay Potluri, Vijay Kamal Ahuja, C N Naveenkumar, Ramya Vadageri Krishnamurthy, Shruthi Thimmalapura Gangadharaiah, Prasad Shivarudraiah, Sumesh Eswaran, Christy Rosaline Nirmal, Balasubramanian Mahizhaveni, Azger Dusthackeer, Rajesh Mondal, Sarah M Batt, Emily J Richardson, Nicholas J Loman, Gurdyal Singh Besra, Radha Krishan Shandil, Shridhar Narayanan

Research output: Contribution to journal › Article › peer-review

260 Downloads (Pure)

Abstract

FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)- [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). In-vitro combination studies of FNDR-20081 with first- and second-line drugs exhibited no antagonism, suggesting its compatibility for developing new combination-regimens. FNDR-20081, which is non-toxic with no CYP3A4 liability, demonstrated exposure-dependent killing of replicating-Mtb, as well as the non-replicating-Mtb, and efficacy in a mouse model of infection. Whole genome sequencing (WGS) of FNDR-20081 resistant mutants revealed the identification of pleotropic targets: marR (Rv0678), a regulator of MmpL5, a transporter/efflux pump mechanism for drug resistance; and Rv3683, a putative metalloprotease potentially involved in peptidoglycan biosynthesis. In summary, FNDR-20081 is a promising first in class compound with the potential to form a new combination regimen for MDR-TB treatment.

Original language	English
Article number	102104
Number of pages	11
Journal	Tuberculosis
Volume	129
Early online date	18 Jun 2021
DOIs	https://doi.org/10.1016/j.tube.2021.102104
Publication status	Published - Jul 2021

Bibliographical note

Keywords

Drug resistance
First-in-class
Multi-target
Mycobacterium tuberculosis
Pre-clinical candidate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tube.2021.102104Licence: None: All rights reserved

KaurP2021multiAccepted author manuscript, 643 KBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Cite this

Kaur, P., Potluri, V., Ahuja, V. K., Naveenkumar, C. N., Krishnamurthy, R. V., Gangadharaiah, S. T., Shivarudraiah, P., Eswaran, S., Nirmal, C. R., Mahizhaveni, B., Dusthackeer, A., Mondal, R., Batt, S. M., Richardson, E. J., Loman, N. J., Besra, G. S., Shandil, R. K., & Narayanan, S. (2021). A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Tuberculosis, 129, Article 102104. https://doi.org/10.1016/j.tube.2021.102104

@article{4a762632a29e4a98abc5e53b49d85ea3,

title = "A multi-targeting pre-clinical candidate against drug-resistant tuberculosis",

abstract = "FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)- [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). In-vitro combination studies of FNDR-20081 with first- and second-line drugs exhibited no antagonism, suggesting its compatibility for developing new combination-regimens. FNDR-20081, which is non-toxic with no CYP3A4 liability, demonstrated exposure-dependent killing of replicating-Mtb, as well as the non-replicating-Mtb, and efficacy in a mouse model of infection. Whole genome sequencing (WGS) of FNDR-20081 resistant mutants revealed the identification of pleotropic targets: marR (Rv0678), a regulator of MmpL5, a transporter/efflux pump mechanism for drug resistance; and Rv3683, a putative metalloprotease potentially involved in peptidoglycan biosynthesis. In summary, FNDR-20081 is a promising first in class compound with the potential to form a new combination regimen for MDR-TB treatment.",

keywords = "Drug resistance, First-in-class, Multi-target, Mycobacterium tuberculosis, Pre-clinical candidate",

author = "Parvinder Kaur and Vijay Potluri and Ahuja, {Vijay Kamal} and Naveenkumar, {C N} and Krishnamurthy, {Ramya Vadageri} and Gangadharaiah, {Shruthi Thimmalapura} and Prasad Shivarudraiah and Sumesh Eswaran and Nirmal, {Christy Rosaline} and Balasubramanian Mahizhaveni and Azger Dusthackeer and Rajesh Mondal and Batt, {Sarah M} and Richardson, {Emily J} and Loman, {Nicholas J} and Besra, {Gurdyal Singh} and Shandil, {Radha Krishan} and Shridhar Narayanan",

year = "2021",

month = jul,

doi = "10.1016/j.tube.2021.102104",

language = "English",

volume = "129",

journal = "Tuberculosis",

issn = "1472-9792",

publisher = "Elsevier",

}

Kaur, P, Potluri, V, Ahuja, VK, Naveenkumar, CN, Krishnamurthy, RV, Gangadharaiah, ST, Shivarudraiah, P, Eswaran, S, Nirmal, CR, Mahizhaveni, B, Dusthackeer, A, Mondal, R, Batt, SM, Richardson, EJ, Loman, NJ, Besra, GS, Shandil, RK & Narayanan, S 2021, 'A multi-targeting pre-clinical candidate against drug-resistant tuberculosis', Tuberculosis, vol. 129, 102104. https://doi.org/10.1016/j.tube.2021.102104

TY - JOUR

T1 - A multi-targeting pre-clinical candidate against drug-resistant tuberculosis

AU - Kaur, Parvinder

AU - Potluri, Vijay

AU - Ahuja, Vijay Kamal

AU - Naveenkumar, C N

AU - Krishnamurthy, Ramya Vadageri

AU - Gangadharaiah, Shruthi Thimmalapura

AU - Shivarudraiah, Prasad

AU - Eswaran, Sumesh

AU - Nirmal, Christy Rosaline

AU - Mahizhaveni, Balasubramanian

AU - Dusthackeer, Azger

AU - Mondal, Rajesh

AU - Batt, Sarah M

AU - Richardson, Emily J

AU - Loman, Nicholas J

AU - Besra, Gurdyal Singh

AU - Shandil, Radha Krishan

AU - Narayanan, Shridhar

PY - 2021/7

Y1 - 2021/7

N2 - FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)- [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). In-vitro combination studies of FNDR-20081 with first- and second-line drugs exhibited no antagonism, suggesting its compatibility for developing new combination-regimens. FNDR-20081, which is non-toxic with no CYP3A4 liability, demonstrated exposure-dependent killing of replicating-Mtb, as well as the non-replicating-Mtb, and efficacy in a mouse model of infection. Whole genome sequencing (WGS) of FNDR-20081 resistant mutants revealed the identification of pleotropic targets: marR (Rv0678), a regulator of MmpL5, a transporter/efflux pump mechanism for drug resistance; and Rv3683, a putative metalloprotease potentially involved in peptidoglycan biosynthesis. In summary, FNDR-20081 is a promising first in class compound with the potential to form a new combination regimen for MDR-TB treatment.

AB - FNDR-20081 [4-{4-[5-(4-Isopropyl-phenyl)- [1,2,4]oxadiazol-3-ylmethyl]-piperazin-1-yl}-7-pyridin-3-yl-quinoline] is a novel, first in class anti-tubercular pre-clinical candidate against sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). In-vitro combination studies of FNDR-20081 with first- and second-line drugs exhibited no antagonism, suggesting its compatibility for developing new combination-regimens. FNDR-20081, which is non-toxic with no CYP3A4 liability, demonstrated exposure-dependent killing of replicating-Mtb, as well as the non-replicating-Mtb, and efficacy in a mouse model of infection. Whole genome sequencing (WGS) of FNDR-20081 resistant mutants revealed the identification of pleotropic targets: marR (Rv0678), a regulator of MmpL5, a transporter/efflux pump mechanism for drug resistance; and Rv3683, a putative metalloprotease potentially involved in peptidoglycan biosynthesis. In summary, FNDR-20081 is a promising first in class compound with the potential to form a new combination regimen for MDR-TB treatment.

KW - Drug resistance

KW - First-in-class

KW - Multi-target

KW - Mycobacterium tuberculosis

KW - Pre-clinical candidate

UR - http://www.scopus.com/inward/record.url?scp=85108880218&partnerID=8YFLogxK

U2 - 10.1016/j.tube.2021.102104

DO - 10.1016/j.tube.2021.102104

M3 - Article

C2 - 34214859

SN - 1472-9792

VL - 129

JO - Tuberculosis

JF - Tuberculosis

M1 - 102104

ER -

A multi-targeting pre-clinical candidate against drug-resistant tuberculosis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this